Cite

    Barrera, J. et al. (2018). Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine. Vaccine. 36 (48), pp. 7345-7352. [Online].